Literature DB >> 16493008

Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Andrea Hoelbl1, Boris Kovacic, Marc A Kerenyi, Olivia Simma, Wolfgang Warsch, Yongzhi Cui, Hartmut Beug, Lothar Hennighausen, Richard Moriggl, Veronika Sexl.   

Abstract

The Stat5 transcription factors Stat5a and Stat5b have been implicated in lymphoid development and transformation. Most studies have employed Stat5a/b-deficient mice where gene targeting disrupted the first protein-coding exon, resulting in the expression of N-terminally truncated forms of Stat5a/b (Stat5a/b(DeltaN/DeltaN) mice). We have now reanalyzed lymphoid development in Stat5a/b(null/null) mice having a complete deletion of the Stat5a/b gene locus. The few surviving Stat5a/b(null/null) mice lacked CD8(+) T lymphocytes. A massive reduction of CD8(+) T cells was also found in Stat5a/b(fl/fl) lck-cre transgenic animals. While gammadelta T-cell receptor-positive (gammadeltaTCR(+)) cells were expressed at normal levels in Stat5a/b(DeltaN/DeltaN) mice, they were completely absent in Stat5a/b(null/null) animals. Moreover, B-cell maturation was abrogated at the pre-pro-B-cell stage in Stat5a/b(null/null) mice, whereas Stat5a/b(DeltaN/DeltaN) B-lymphoid cells developed to the early pro-B-cell stage. In vitro assays using fetal liver-cell cultures confirmed this observation. Most strikingly, Stat5a/b(null/null) cells were resistant to transformation and leukemia development induced by Abelson oncogenes, whereas Stat5a/b(DeltaN/DeltaN)-derived cells readily transformed. These findings show distinct lymphoid defects for Stat5a/b(DeltaN/DeltaN) and Stat5a/b(null/null) mice and define a novel functional role for the N-termini of Stat5a/b in B-lymphoid transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493008      PMCID: PMC2875852          DOI: 10.1182/blood-2005-09-3596

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

Review 1.  A new modality for immunosuppression: targeting the JAK/STAT pathway.

Authors:  John J O'Shea; Marko Pesu; Dominic C Borie; Paul S Changelian
Journal:  Nat Rev Drug Discov       Date:  2004-07       Impact factor: 84.694

2.  Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation.

Authors:  Yongzhi Cui; Greg Riedlinger; Keiko Miyoshi; Wei Tang; Cuiling Li; Chu-Xia Deng; Gertraud W Robinson; Lothar Hennighausen
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

3.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.

Authors:  Y Shinkai; G Rathbun; K P Lam; E M Oltz; V Stewart; M Mendelsohn; J Charron; M Datta; F Young; A M Stall
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

4.  STAT5 is required for thymopoiesis in a development stage-specific manner.

Authors:  Joonsoo Kang; Brian DiBenedetto; Kavitha Narayan; Hang Zhao; Sandy D Der; Cynthia A Chambers
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

Review 5.  STAT proteins as novel targets for cancer drug discovery.

Authors:  James Turkson
Journal:  Expert Opin Ther Targets       Date:  2004-10       Impact factor: 6.902

6.  STAT5 activation underlies IL7 receptor-dependent B cell development.

Authors:  Christine A Goetz; Ian R Harmon; Jennifer J O'Neil; Matthew A Burchill; Michael A Farrar
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

7.  Functional dissection of the murine lck distal promoter.

Authors:  R S Wildin; H U Wang; K A Forbush; R M Perlmutter
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

8.  Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.

Authors:  J J Peschon; P J Morrissey; K H Grabstein; F J Ramsdell; E Maraskovsky; B C Gliniak; L S Park; S F Ziegler; D E Williams; C B Ware; J D Meyer; B L Davison
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

9.  Developmental regulation of lck gene expression in T lymphocytes.

Authors:  R S Wildin; A M Garvin; S Pawar; D B Lewis; K M Abraham; K A Forbush; S F Ziegler; J M Allen; R M Perlmutter
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

10.  Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.

Authors:  N Carlesso; D A Frank; J D Griffin
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  117 in total

1.  The SH2B1 adaptor protein associates with a proximal region of the erythropoietin receptor.

Authors:  Mojib Javadi; Edda Hofstätter; Natalie Stickle; Bryan K Beattie; Robert Jaster; Christin Carter-Su; Dwayne L Barber
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  Critical requirement for Stat5 in a mouse model of polycythemia vera.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

3.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

4.  The gene encoding the hematopoietic stem cell regulator CCN3/NOV is under direct cytokine control through the transcription factors STAT5A/B.

Authors:  Akiko Kimura; Cyril Martin; Gertraud W Robinson; James M Simone; Weiping Chen; Mark C Wickre; John J O'Shea; Lothar Hennighausen
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

5.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Authors:  Oliver Hantschel; Wolfgang Warsch; Eva Eckelhart; Ines Kaupe; Florian Grebien; Kay-Uwe Wagner; Giulio Superti-Furga; Veronika Sexl
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

6.  SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation.

Authors:  Thang Van Nguyen; Pornpimon Angkasekwinai; Hong Dou; Feng-Ming Lin; Long-Sheng Lu; Jinke Cheng; Y Eugene Chin; Chen Dong; Edward T H Yeh
Journal:  Mol Cell       Date:  2012-01-27       Impact factor: 17.970

7.  The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5.

Authors:  Darshana Kadekar; Rasmus Agerholm; John Rizk; Heidi A Neubauer; Tobias Suske; Barbara Maurer; Monica Torrellas Viñals; Elena M Comelli; Amel Taibi; Richard Moriggl; Vasileios Bekiaris
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

8.  Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

Authors:  Suhu Liu; Sarah R Walker; Erik A Nelson; Robert Cerulli; Michael Xiang; Patricia A Toniolo; Jun Qi; Richard M Stone; Martha Wadleigh; James E Bradner; David A Frank
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

9.  STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.

Authors:  Geqiang Li; Kristy L Miskimen; Zhengqi Wang; Xiu Yan Xie; Jennifer Brenzovich; John J Ryan; William Tse; Richard Moriggl; Kevin D Bunting
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

10.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.